Acrivon Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2021 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Acrivon Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2021 to 2023.
  • Acrivon Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$22.4M, a 55.1% decline year-over-year.
  • Acrivon Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$77M, a 53.8% decline year-over-year.
  • Acrivon Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$60.4M, a 93.8% decline from 2022.
  • Acrivon Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$31.2M, a 91.9% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$60.4M -$29.2M -93.8% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-28
2022 -$31.2M -$14.9M -91.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 -$16.2M Jan 1, 2021 Dec 31, 2021 10-K 2023-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.